领誉环球 | 康维讯生物创始人获AllAroundWorlds国际媒介报道

Emerging Global Leaders Shaping the Future in 2026 —— Linglong Zou

《2026塑造未来的新兴全球领袖》 —— 邹灵龙博士

【高光时刻，加冕前行】

近日，康维讯生物创始人、董事长兼CEO 邹灵龙博士在全球具有影响力的AllAroundWorlds国际门户上，选为2026塑造未来的新兴全球领袖（Emerging Global Leaders Shaping the Future in 2026）之一，并在多个国际主流社交媒体上同步发布相关报道。凭借邹灵龙博士在全球生物分析与新药研发领域的卓越建树，引发国内外行业领域的高度关注与热烈反响，此次，由邹灵龙博士带领企业步入国际化舞台并再添一抹亮色。

Linglong Zou

Company: Kanwhish Biotech Co.

Designation: Founder

Country: China

Social Media Links

Linkedin: https://www.linkedin.com/in/linglongzou

Linglong Zou, PhD, stands among the emerging global leaders shaping the future of biologics development,  bioanalytical sciences and technologies through a career defined by scientific depth, technology innovation, regulatory impact, and innovation-led leadership. With more than two decades of industry experience, Dr. Zou has played a significant role in advancing biologic and biosimilar development on a global scale, helping expand patient access to life-changing therapies globally.

He earned his doctorate in Pharmacology from Chinese Academy of Sciences and completed postdoctoral training at Baylor College of Medicine, USA before entering the industry in 2001 as an analytical and bioanalytical scientist at Tanox, Inc., a Genentech company. This early foundation in rigorous scientific research set the stage for a career focused on both technical excellence and real-world therapeutic impact.

Dr. Zou went on to hold senior leadership roles at Teva Pharmaceuticals USA and Henlius Biotech Co., where his responsibilities steadily expanded across bioanalytical strategy, assay development, and regulatory support. As Senior Director of Biologic Assays and Technology at Teva and later General Manager of Bioanalytical Sciences at Henlius, he was instrumental in supporting the bioanalysis and regulatory approval of 16 biologic products worldwide, including nine biosimilars referencing major therapies such as Herceptin, Avastin, Rituxan, and Humira. These programs have significantly reduced treatment costs while improving access to critical therapies for patients with cancer and autoimmune diseases.

In 2022, motivated by the opportunity to apply his expertise more broadly, Dr. Zou founded Kanwhish Biotech Co., a bioanalytical-focused contract research organization headquartered in Suzhou, China. Since its inception, Kanwhish has supported more than 100 global clients, delivering high-quality bioanalytical services across a wide range of development programs. In alignment with evolving FDA initiatives aimed at accelerating biosimilar development and lowering drug costs, the company has expanded its analytical capabilities and established strategic partnerships with biologics CDMOs and clinical CROs, enabling integrated, end-to-end development solutions.

Known for his innovation-driven mindset, Dr. Zou has developed multiple novel technologies, methodologies, and tools that address long-standing challenges in bioanalysis. His work includes the creation of a generic bioanalytical assay platform for preclinical pharmacokinetic and anti-drug antibody assessments of complex biologics, significantly reducing assay development timelines. He has also introduced practical solutions to overcome drug interference in clinical immunogenicity testing through the design of compact, magnetic-bead–based sample pretreatment devices and cost-effective automation platforms.

Guided by a strong quality-by-design philosophy, Dr. Zou continues to transform bioanalysis into a more efficient, reliable, and scalable discipline. His leadership bridges scientific rationale and technology innovation with operational execution, positioning him as a global contributor to the future of biologics, biosimilars, and accessible healthcare product development.

译文：

邹灵龙博士是全球生物分析科学与技术领域的领军人物之一。他的职业生涯以生物分析检测技术的持续创新为标志，拥有超过二十年的行业经验，邹博士作为生物分析科学家在全球范围内推动多款创新生物药和生物类似药的研发，帮助全球更多患者获得改变生命的疗法。

他在中国科学院上海药物研究所获得药理学博士学位，并在美国贝勒医学院完成博士后训练后，于2001年进入工业界，在后为基因泰克合并的Tanox公司担任药物分析及生物分析科学家，在多个创新生物药的开发中历练。这段在严谨科学研究中的早期经历，为他日后专注于技术创新的职业生涯奠定了基础。

此后，邹博士在美国梯瓦制药和复宏汉霖担任生物分析的高级领导职务，其职责范围稳步拓展至生物分析策略、检测方法开发和法规支持等领域。在梯瓦担任生物检测与技术开发高级总监，以及在复宏汉霖担任生物分析总经理期间，他支持了总计16个生物药的生物分析，并在全球获批上市，其中包括9个重要的生物类似药，譬如赫赛汀、安维汀、美罗华和修美乐等的生物类似药。这些药物的成功开发与上市显著降低了治疗成本，给全球的癌症和自身免疫性疾病患者带来了质高价优的关键疗法。

2022年，出于在更广泛领域应用其专业知识的愿望，邹博士创立了康维讯生物科技（Kanwhish Biotech Co.），这是一家总部位于中国苏州、专注于生物分析的合同研究组织。自成立以来，康维讯生物已为全球超过100家客户提供了支持，在丰富的开发项目中交付了高质量的生物分析服务。为顺应美国食品药品监督管理局（FDA）旨在加速生物类似药开发和降低药物成本的新举措，公司已扩展其分析能力，并与生物药合同开发生产组织（CDMOs）和临床合同研究组织（CROs）建立了战略合作伙伴关系，从而能够提供一体化的端到端的开发服务。

邹博士以其创新驱动的思维开发了多项解决生物分析中长期挑战的新技术、新方法和新工具。他创建了一个用于抗体类药物临床前药代动力学和抗药抗体评估的通用生物分析检测平台，显著缩短了相关检测方法的开发周期。他还通过设计小型的基于磁珠的样本预处理装置和具有成本效益的自动化平台，引入了实用的解决方案来克服临床免疫原性测试中的药物干扰问题。

基于"质量源于设计"的理念，邹博士的创新将持续推动生物分析向更高效、可靠和可扩展的学科转变。他的领导力将科学原理、技术创新与运营执行紧密相连，这使他成为全球创新性生物与药生物类似药以及可及性医疗产品未来发展的贡献者。

关于AllAroundWorlds

Amplifying Stories That Inspire the World

AllAroundWorlds was born with a mission: to bring the voices of innovators, visionaries, and changemakers to a global stage. Over the past year, we’ve proudly featured the incredible journeys of more than 500 leaders from across the globe – stories that spark inspiration, provoke thought, and ignite action.

With our growing audience of over 40K monthly visitors, AllAroundWorlds is more than just a publication it's a movement now. We are here to share the success of those who are shaping industries and the future.

Bringing Global Journeys to Life

Welcome to AllAroundWorlds, your gateway to the inspiring journeys and stories of visionary leaders from around the globe. Our platform is dedicated to showcasing the unique paths of individuals who are making an impact in various fields, offering insights that resonate with a global audience. From leadership journeys to innovations and cultural insights, we bring you engaging content that connects minds and inspires action.

关于康维讯生物

康维讯生物由经验丰富的生物分析专家团队领衔成立，提供全方位、一站式的生物分析服务，涵盖临床前/临床药代动力学、药效学、免疫原性、生物标志物、生物活性分析、中心实验室样本管理。康维讯生物已建成免疫检测分析平台、分子检测分析平台以及细胞学分析平台等技术平台，在苏州吴中生物医药产业园设有3,000平米GLP检测服务实验室，包括适合CGT和ADC产品生物分析的十万级净化实验室，BSL-2级实验室，PCR分析实验室，配备生物分析专业管理系统和高端/专业检测仪器，实验室GLP质量体系、ISO9001质量认证可同时满足全球监管机构的申报要求。旗下子公司维康利生物聚焦CGT产品的药学分析与质量检测，提供从临床前到药品商业化的全阶段药学分析与质量检测服务。

康维讯生物团队累积了多年的生物分析经验，将坚持“推动生物行业发展，助力新药研发”的使命，以助力创新型药物上市为己任，致力于成为全球药企生物分析最值得信赖的合作伙伴。康维讯生物以创新技术为基石，提供质高价优、符合全球监管机构要求的生物分析服务，助力药物研发企业降低研发成本，提高申报成功率，加速申报进程。

成立以来，康维讯生物已荣获多项能力认证和奖项：第六届、第五届、第四届国际细胞与基因治疗中国峰会「CGT领域CRO合作启明星奖」、第五届亚洲生物制药创新峰会「最具潜力的ADC与双抗药物生物分析CRO TOP10」、第五届生物药开发者创新大会「年度最优品质服务奖」、中国生物医药产业价值榜「最佳服务供应商TOP10」、入驻国际主流供应商采购网站「Scientist.com」、国际期刊Life Sciences Review评选为「TOP BIOTECH COMPANY IN CHINA」。

更多信息，请访问康维讯生物官方网站：
www.kanwhish.com